Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
29/09/2026 12:30
BRIEF-Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab) Sept 29 (Reuters) - Knight Therapeutics Inc GUD.TO:
KNIGHT THERAPEUTICS ENTERS INTO EXCLUSIVE DISTRIBUTION AGREEMENT WITH KYOWA KIRIN INTERNATIONAL FOR POTELIGEO® (MOGAMULIZUMAB)
KNIGHT THERAPEUTICS - TO OBTAIN REGULATORY APPROVAL AND COMMERCIALIZE POTELIGEO IN BRAZIL, MEXICO, COLOMBIA, ARGENTINA
Source text: ID:nGNX2dsCPc
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil